This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Charo, J.
Right arrow Articles by Kiessling, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Charo, J.
Right arrow Articles by Kiessling, R.

 Previous Article  |  Next Article 

Infection and Immunity, December 2002, p. 6652-6657, Vol. 70, No. 12
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.12.6652-6657.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Marked Enhancement of the Antigen-Specific Immune Response by Combining Plasmid DNA-Based Immunization with a Schiff Base-Forming Drug

Jehad Charo,1,2* Maria Sundbäck,1 Ken Wasserman,3 Anne-Marie T. Ciupitu,1 Babak Mirzai,2 Ruurd van der Zee,4 and Rolf Kiessling1,2

Cancer Center Karolinska (CCK), Karolinska Hospital, S-17176,1 Microbiology and Tumor Biology Center (MTC), Karolinska Institute, S-17177, Stockholm, Sweden,2 American Type Culture Collection, Manassas, Virginia 20110,3 Department of Immunology, Faculty of Veterinary Medicine, Utrecht University, 3508 TD Utrecht, The Netherlands4

Received 20 May 2002/ Returned for modification 28 June 2002/ Accepted 13 September 2002

Although plasmid DNA (pDNA)-based immunization has proven efficacy, the level of immune responses that is achieved by this route of vaccination is often lower than that induced by traditional vaccines, especially for primates and humans. We report here a simple and potent method to enhance pDNA-based vaccination by using two different plasmids encoding viral or bacterial antigens. This method is based on coadministration of low concentrations of a recently described immunopotentiating, Schiff base-forming drug called tucaresol which has led to significant augmentation of antigen-specific humoral and cellular immune responses. Our data suggest that enhancement of the immune response with tucaresol might provide a powerful tool for the further development of pDNA-based immunization for humans.

* Corresponding author. Present address: Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, 10 Center Dr., Bethesda, MD 20892. Phone: (301) 496-9383. Fax: (301) 496-0011. E-mail: Jehad_Charo{at}nih.gov.

Editor: J. D. Clements

Infection and Immunity, December 2002, p. 6652-6657, Vol. 70, No. 12
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.12.6652-6657.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Charo, J., Lindencrona, J. A., Carlson, L.-M., Hinkula, J., Kiessling, R. (2004). Protective Efficacy of a DNA Influenza Virus Vaccine Is Markedly Increased by the Coadministration of a Schiff Base-Forming Drug. J. Virol. 78: 11321-11326 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»